drugset / Trial / NCT03199690
A Clinical Study Investigating Rifampicin and Dolutegravir in Combination in Healthy Volunteers
SequentialOpen-labelTreatment
Summary
The purpose of the study is to see how the drug Dolutegravir is broken down by your body, when taken with another drug called Rifampicin. Dolutegravir is given to people as a treatment for HIV. Rifampicin is given to people as a treatment for tuberculosis.
Timeline
- Start
- 2017-10
- Primary completion
- 2018-03
- Completion
- 2018-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dolutegravir | Other / unclassified | 50 mg | — |
| Subject | Dolutegravir | Other / unclassified | 100 mg | — |
| Subject | Rifampin | Small molecule | 600 mg | — |